| Authors: |
Piha-Paul S; Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Olwill SA; Department of Research and Development, Pieris Pharmaceuticals GmbH, Bavaria, Germany., Hamilton E; Department of Oncology, Sarah Cannon Research Institute/Tennessee Oncology, LLC, Nashville, Tennessee., Tolcher A; NEXT Oncology, San Antonio, Texas., Pohlmann P; Department of Medicine, Georgetown University Lombardi Comprehensive Cancer Center, Washington, District of Columbia., Liu SV; Department of Medicine, Georgetown University Lombardi Comprehensive Cancer Center, Washington, District of Columbia., Wurzenberger C; Department of Research and Development, Pieris Pharmaceuticals GmbH, Bavaria, Germany., Hasenkamp LC; Department of Research and Development, Pieris Pharmaceuticals GmbH, Bavaria, Germany., Hansbauer EM; Department of Research and Development, Pieris Pharmaceuticals GmbH, Bavaria, Germany., Shroff R; Department of Medicine, University of Arizona Cancer Center, Tucson, Arizona., Hurvitz S; Department of Medicine, University of California Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, California., Krishnamurthy A; University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania., Patnaik A; Department of Phase I Research, The START Center for Cancer Research, San Antonio, Texas., Hahn N; Department of Oncology and Urology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland., Kumar R; Department of Research and Development, Pieris Pharmaceuticals GmbH, Bavaria, Germany., Duerr M; Department of Research and Development, Pieris Pharmaceuticals GmbH, Bavaria, Germany., Zettl M; Department of Research and Development, Pieris Pharmaceuticals GmbH, Bavaria, Germany., Aviano K; Department of Research and Development, Pieris Pharmaceuticals, Inc., Boston, Massachusetts., Matis L; Department of Research and Development, Pieris Pharmaceuticals, Inc., Boston, Massachusetts., Bruns I; Department of Research and Development, Pieris Pharmaceuticals, Inc., Boston, Massachusetts., Ku G; Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. |
